Personal tools

Offene Studien fortgeschritten


A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease


A phase II multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment

Detect IIIEine Multizentrische, prospektiv randomisierte Phase III Studie zum Vergleich einer antineoplastischen Therapie allein versus einer antineoplastischen Therapie plus Lapatinib bei Patientinnen mit initial HER2-neg. metastasiertem Brustkrebs und HER“-pos. zirkulierenden Tumorzellen
Detect IVMultizentrische, prospektive einarmige Phase II Studie zur Evaluation der Effektivität von Everolismus mit einer endokrinen Standardtherapie bei Patientinnen mit hormonrezeptorpositiven, Her2-neg.metastasiertem Brustkrebs und Her2 neg. zirkulierende Tumorzellen
Detect VA multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Pertuzumab in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
DESIREEA multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer

Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009).


A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.


A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer


Prospektive, randomisierte, monozentrische Studie zum Einfluss einer intensiven Ernährungsberatung auf die Lebensqualität bei Patienten mit metastasiertem Brustkrebs unter CDK4/6- oder mTOR-Inhibition


International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second-line endocrine therapy in Hormone Receptor-positive/HER2-negative advanced breast cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment.


Prospektives akademisches translationales Forschungsnetzwerk zur Optimierung der onkologischen Versorgungsqualität in der adjuvanten und fortgeschrittenen/ metastasierten Situation (Registerstudie)

ViolettePhase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)